5-aza-2'-deoxycytidine처치에 의해 유도되는 B16F10 세포주의 유전자 발현

김태종; 채한수; 손진식; 송달원; 박종욱

추천

검색

자료유형: 학술저널

저자정보: 김태종 채한수 손진식 송달원 박종욱

저널정보: 대한이비인후과학회 대한이비인후-두경부외과학회지 대한이비인후과학회지 두경부외과학 제45권 제8호

발행연도: 2002.1

수록면: 784 - 790 (7page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background and Objectives：by a tumor, and many types of vaccines such as gene modified vaccines have been developed to increase imunogenicity of vaccine. We studied to determine whether or not 5-aza-2-deoxycytidine (ADC) can increase the immunogenicity of B16F10 melanoma cell. Materials and Method：B16F10 cell was treated with ADC for the induction of DNA demethylation. An ADC treated B16F10 melanoma cell was analyzed first using the reverse transcriptase-polymerase chain reaction (RT-PCR) (MAGE-2, MAGE-5) and immunity-enhancing cytokines (GM-CSF, IL-12), and then by flow cytometry to evaluate the expression of MHC and B7 that are responsible for antigen expres-sion and T cell activation on B16F10 cell surface. In order to evaluate vaccination effect of ADC-treated B16F10 vaccine, each mouse group were injected with PBS, ADC, B16F10 vaccine or B16F10-ADC vaccine and they were also challenged with live B16F10 cell 7 days after vaccination. On the 20th day after live B16F10 cell challenge, the tumor mass size and the Results：ADC treatment for B16F10 melanoma cell increased expresion of MHC and B7. ADC treatment also increased gene expresion of MAGE-2, MAGE-5, GM-CSF and IL-12. The growth of tumor mass was decreased and the mouse survival period was elongated in B16F10-ADC vaccine imunized group. Conclusion：ADC treatment may increase imunogenicity of B16F10 cell, and B16F10-ADC vaccine imunization can induce anti-cancer imunity in vivo. (Korean J Otolaryngol 2002;45:784-90)

#5-aza-2' -deoxycytidine·흑색종·종양백신. #5-aza-2-deoxycytidine· Melanoma· Cancer vaccine.

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!